Ann: Syd Capital Markets Briefing Presentation, page-12

Looks like you've been here 5 minutes. Clinuvel has one approved indication after nearly 10 years, made the mistake of assuming they wouldn't need to do a trial for paediatric EPP which led to delays, their drug has been approved in Australia for a few years and no progress with the PBS (we know why, its pricing), no progress in China and Japan yet they deemed it news worthy to announce their intention of dealing in China, stubbornness in their refusal to enact a flexible pricing regime (nobody needs to know what market is paying what) etc tec. From all the press releases over the past decade you'd think there's a lot going on, and there may well be. But it hasn't translated to positive results at least where the share price is concerned.

Neuracthel sNDA scheduled for submission in 2026. WHAT? A generic drug that will have been 5-6 years in development by the time it's approved. Biotech is a long game if you're investing in Clinuvel.